Interferon Kappa

Summary

Interferon kappa (IFN-κ) is a naturally occurring type I interferon predominantly expressed in keratinocytes and dendritic cells. It shares antiviral and immunomodulatory properties with other type I interferons but has a more restricted expression pattern. It has been studied in the context of skin immunity, lupus erythematosus, HPV infection, and innate immune responses. No approved therapeutic formulation exists; it remains a research-stage molecule.

Mechanism of Action

Binds to the type I interferon receptor (IFNAR1/IFNAR2 heterodimer), activating the JAK-STAT signaling pathway (JAK1/TYK2), leading to transcription of interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects.

Routes of Administration

No administration routes recorded yet.

Goals & Uses

• Antiproliferative / antitumor effectsOncologyLow
• Autoimmune disease research (SLE/lupus)Immunology / AutoimmunityModerate
• HPV suppressionAntiviralModerate
• Antiviral defense in skinImmunology / AntiviralModerate

Contraindications

• Severe autoimmune disordersAutoimmunityModerate
• Hypersensitivity to type I interferonsAllergy / ImmunologyHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalUnknown
• Injection site reactionsLocalUnknown
• Immunomodulatory dysregulationImmunologyUnknown

Drug Interactions

• JAK inhibitors (e.g., tofacitinib, ruxolitinib)High
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric populationAgeRelative
• Patients with active autoimmune diseaseImmunologicalRelative

Regulatory Status

• European UnionUnapprovedNo EMA-approved therapeutic product. Research use only.
• United StatesUnapprovedNo FDA-approved therapeutic product. Research use only.
• United KingdomUnapprovedNo MHRA-approved therapeutic product. Research use only.

IFN-κ has not been approved as a therapeutic agent by any major regulatory authority (FDA, EMA, MHRA). It is studied in research and preclinical contexts. No IND or clinical trial approvals are widely documented for a therapeutic IFN-κ product.

Evidence & Sources

No sources recorded yet.